scholarly journals Kangai Injection Combined with Platinum-based Chemotherapy for the Treatment of Stage III/IV Non-Small Cell Lung Cancer: A Meta-analysis and Systematic Review of 35 Randomized Controlled Trials

2019 ◽  
Vol 10 (21) ◽  
pp. 5283-5298 ◽  
Author(s):  
Hongxiao Li ◽  
Yuejin Ji ◽  
Shiping Zhang ◽  
Zishan Gao ◽  
Cheng Hu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Systematic Review ◽  
Small Cell Lung Cancer ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Small Cell ◽  
Controlled Trials ◽  
Small Cell Lung ◽  
Randomized Controlled ◽  
Platinum Based Chemotherapy

Topotecan plus Platinum-Based Chemotherapy versus Etoposide plus Platinum-Based Chemotherapy for Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Chemotherapy ◽  
2021 ◽  
pp. 1-11
Author(s):  
Mengyu He ◽  
Bingxuan Wu ◽  
Qiangyun Liu ◽  
Zige Fang ◽  
Miaowen Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Randomized Controlled Trials ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Controlled Trials ◽  
Small Cell Lung ◽  
Randomized Controlled ◽  
Platinum Based Chemotherapy

<b><i>Background:</i></b> Whether topotecan plus platinum-based chemotherapy (TP) can achieve better results than etoposide plus platinum-based chemotherapy (EP) for small-cell lung cancer (SCLC) treatment is still controversial in clinical applications. We compared the effectiveness and toxicity of TP versus EP in this meta-analysis. <b><i>Methods:</i></b> We searched PubMed, ScienceDirect, Cochrane Library, Scopus, Ovid MEDLINE, Embase, Web of Science, and Google Scholar databases for completeness one by one to find articles that met the conditions. Overall survival (OS) and progression-free survival (PFS) were analyzed as primary endpoints, and the objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) were analyzed as secondary endpoints. <b><i>Results:</i></b> In total, 2,480 articles were retrieved, and 6 randomized controlled trials (RCTs) contained results based on 1,924 patients. EP suggested conspicuously better OS (hazard ratio [HR]: 1.24 [1.02, 1.50], <i>p</i> = 0.03) and PFS (HR: 1.39 [1.17, 1.64], <i>p</i> = 0.0001) in SCLC treatment than TP, and ORR (54.1% vs. 60.2%, risk ratio [RR]: 0.77 [0.57, 1.06], <i>p</i> = 0.11), and DCR (74.9% vs. 84.4%, RR: 0.89 [0.79, 1.00], <i>p</i> = 0.06) tended to favor EP. Subgroup analysis of subsistence showed that EP had prominent benefit in the following subgroups: Asian, median age &#x3e; 60, first-line treatment, ECOG 0–2, intravenous topotecan, and cisplatin. AEs illustrated that EP had conspicuously more anemia and alopecia than TP. <b><i>Conclusions:</i></b> Compared with TP, EP was noticeably better in OS and PFS, but EP was toxic in terms of anemia and alopecia. More multicenter, better planned RCTs are needed.

Sign in / Sign up

Export Citation Format

Share Document